Tech Company Financing Transactions
Kivu Bioscience Funding Round
Novo Holdings, BioGeneration Ventures and BOM invested in a $92 million Series A funding round for Kivu Bioscience. The round was announced on 10/28/2024.
Transaction Overview
Company Name
Announced On
10/28/2024
Transaction Type
Venture Equity
Amount
$92,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for the clinical development of multiple ADC programs.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
One Market Plaza, 17th Floor of the Steuart Tower
San Francisco, CA 94105
USA
San Francisco, CA 94105
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept. Guided by rigorous science and a commitment to addressing unmet medical needs, our experienced team collaborates with global partners and key opinion leaders to accelerate the delivery of life changing antibody-drug conjugates (ADCs) that aim to conquer cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
President
Mohit Trikha
Vice President
Ann MacLaren
Vice President
Liangyi Zhang
Browse more venture capital transactions:
Prev: 10/28/2024: nfinite venture capital transaction
Next: 10/28/2024: Reflexivity venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs